Author: Site Editor Publish Time: 2026-11-20 Origin: Site
COMPANY NEWS · MEDICA 2026
New launches and integrated Diabetes-CKD solutions
Düsseldorf, Germany · 19 November 2026 · Hall 1 · Stand B56
Today marks the successful conclusion of MEDICA 2026 (16–19 November 2026, Messe Düsseldorf). Marking 27+ years of dedication to in vitro diagnostics (IVD) R&D and manufacturing since 1999—with a footprint spanning China and 100+ countries worldwide—Goldsite Diagnostics welcomed laboratory professionals, clinicians, and global partners to Hall 1 · Stand B56, showcasing a comprehensive portfolio anchored by its flagship HbA1c and Specific Protein lines alongside integrated Diabetes-CKD co-management solutions (Goldsite MEDICA 2026; Goldsite Diabetes-CKD Solutions).
Goldsite Diagnostics at Hall 1 · Stand B56, MEDICA 2026.
01 — CORE LINES
At Stand B56, Goldsite’s HbA1c and Specific Protein portfolios drew strong interest from high-volume laboratories, specialty clinics, and regional distributors:
HPLC HbA1c Portfolio (GSH-50 / GSH-60 / GSH-120)
Highlighted by the world premiere of the GSH-120, Goldsite’s high-throughput ion-exchange HPLC analyzer delivers up to 120 tests/hour from just 3 µL of whole blood with direct cap-piercing, clear separation of common hemoglobin variants (HbE, HbD, HbS, HbC), and multi-unit cascading/track connectivity. Alongside it, the GSH-60 and GSH-50 address mid- and compact-throughput HPLC laboratory needs.
POCT HbA1c (A1c Go)
A cartridge-based boronate affinity chromatography analyzer offering one-step automatic testing from 5 µL of blood with results in ≤ 5 minutes for primary care and mobile screening.
Goldsite HPLC HbA1c lineup: GSH-50 / GSH-60 / GSH-120.
Specific Protein Systems (Aristo & GPP-100)
The Aristo fully automated nephelometry system brings up to 200 samples/hour throughput and 45+ assays (spanning inflammation, immunology, complement, rheumatology, cardiovascular, and renal markers) to high-volume labs, while the compact GPP-100 delivers 20+ cartridge-based quantitative assays in a smart, maintenance-free footprint.
GSH-120 HPLC HbA1c Analyzer, world premiere at MEDICA 2026.
02 — ON DISPLAY
Beyond HbA1c and specific proteins, visitors explored Goldsite’s broader diagnostic lineup built for diverse laboratory settings:
FIA GO (POCT · TRFIA)
Compact (~2 kg) time-resolved fluorescence immunoassay analyzer achieving 100–200 tests/hour with quantitative results in minutes.
GH-3100 (Hematology)
Compact automatic 3-part differential hematology analyzer delivering 21 parameters + 3 histograms at up to 60 samples/hour.
GBA-1000 (Biochemistry)
Open-system benchtop clinical chemistry analyzer with 45 onboard-cooled reagent positions and ~100 tests/hour throughput for clinics, small labs, and ERs.
Goldsite Exhibits on MEDICA 2026
03 — CLINICAL CARE
Aligned with KDIGO 2024 and ADA Standards of Care 2025 guidelines—which emphasize shifting from glycemic control alone to combined cardio-renal protection—Goldsite highlighted its Diabetes-CKD co-management strategy (Goldsite Diabetes-CKD Solutions). By pairing HPLC HbA1c (2–3 month glycemic control) with specific protein testing (UACR and early glomerular/tubular injury markers such as urinary transferrin, IgG, α1-MG, RBP, and serum Cystatin C), laboratories can close diagnostic blind spots caused by metabolic memory. Combining Goldsite’s HPLC HbA1c analyzers with Aristo Ur—a dual-methodology (immunonephelometry + spectrophotometry, 200 tests/hour) system that automatically reports ACR and multiple urinary protein-to-creatinine ratios—equips endocrinology and nephrology teams with a practical, end-to-end diagnostic pairing.
HbA1c, UACR Diabetes-CKD solutions.
04 — LOOKING AHEAD
As MEDICA 2026 concludes today, Goldsite Diagnostics extends its sincere appreciation to every visitor, distributor, and clinical partner who connected with us at Hall 1 · Stand B56. We look forward to building on the momentum from Düsseldorf to bring accessible, reference-grade diagnostic solutions to laboratories worldwide.
Goldsite Diagnostics Inc. · en.goldsite.com.cn